B2M and central nervous system cancer: In addition, B2M levels in IDH1 mutant glioma (weak intensity 58.7%; moderate intensity 37%; strong intensity 4.3%) samples were lower than those in IDH1 wild‐type (weak intensity 14%; moderate intensity 40.4%; strong intensity 45.6%) samples(Figure 3C,D, Z = −5.534, p < 0.01).